Vivid Genomics 

Enabling drug development for dementia.


Julie Collens, PhD


Vivid Genomics is a precision medicine company that enables pharma companies to select and stratify the right patients for their clinical trials, increasing the probability of trial success and drug approval.

We use machine learning and genomics to develop blood-based, genetic tests (“Genomic BiopsyTM”) for neurodegenerative diseases. Our first two tests will address features of Alzheimer’s disease:

AmyloidGB™ Predicts the presence of amyloid plaques, a hallmark of Alzheimer’s disease for precision patient enrollment, enriching the subset of patients who will be positive in Amyloid PET.

ProgressionGB™ Provides information on predicted Alzheimer’s disease progression rate for precision balancing of the trial arms. It can be used for retrospective analysis to determine if a trial would have been successful by balancing for progression rate or removal of non-progressors.


  • Selected as Xconomy Awards Finalist
  • San Diego Venture Group Announces Vivid Genomics as a “Cool Company”
  • Awarded grant from Intermountain Health
  • AI Med North America Shark Tank 2018 Finalists Announced / Winner: Vivid Genomics!
  • Selected for Ad Astra Accelerator
Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from - Youtube
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google